Back to News
Market Impact: 0.15
Barclays Initiates Coverage of Humacyte at Equal-Weight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 7, 2026, Barclays initiated coverage of Humacyte with an Equal-Weight recommendation. Barclays had maintained an Overweight rating on April 8, 2026; the article provides no further details or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.10
More News
- Susquehanna raises Marvell stock price target on data center growth
- Cantor Fitzgerald lowers Arthur J. Gallagher price target on EPS cuts
- W P Carey stock hits 52-week low at 63.08 USD
- European bank shares fall as bond yields surge, spreads widen
- Exclusive: Meet the 38-year-old founder who left Wall Street for love and created an AI insurance unicorn a decade later
- Existential threats join bubble fears as AI mood sobers at Singapore forums